Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 04.01.2024
Aquis Stock Exchange
The following securities will be withdrawn from trading in the Aquis Stock Exchange Growth Market with effect from market open today, 4 January 2024:
MBH Corporation Plc
Ordinary shares
Symbol: M8H
ISIN: GB00BPNYZL95
Aquis Stock Exchange
Floor 2, 63 Queen Victoria Street, EC4N 4UA
Tel: 0203 597 6361
Email: aqseregulation@aquis.eu
Website: www.aquis [ … ]
Thu, 04.01.2024
Aquis Stock Exchange
The following securities are suspended from trading on the Aquis Growth Market with effect from 08:00, 04/01/2024:
Looking Glass Labs Limited
Common Shares
Symbol: NFTX
ISIN: CA54342Q2053
The Regulation Department
Aquis Stock Exchange
Floor 2, 63 Queen Victoria Street, EC4N 4UA
Tel: 0203 597 6361
Email: aqseregulation@aquis.eu
Website: www.aquis.eu [ … ]
Thu, 04.01.2024
Evotec SE
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM
A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC
AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC
Hamburg, Germany, and Paris, France, 04 Janu [ … ]
Thu, 04.01.2024
Nordex SE
Hamburg, 4 January 2024. End of 2023, the Nordex Group received an order from Capital Energy for 106 MW in Spain. In spring 2025 the Nordex Group will be delivering and installing 18 N163/5.X turbines for the “Mareas I & II” wind farm near Mequinenza in the province of Zaragossa. The turbines from the Delta4000 series will be installed on tubul [ … ]
Thu, 04.01.2024
Newron Pharmaceuticals S.p.A.
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF)
More than 70% of patients experienced clinically im [ … ]
Thu, 04.01.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Study results/Preliminary Results
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA 04.01.2024 / 07:00 CET/CEST
New level 1 data from the MAXA [ … ]
Thu, 04.01.2024
GRENKE AG
GRENKE continues its profitable growth path: EUR 2.6 billion in new leasing business in 2023
New leasing business in 2023 surpasses previous year's level by 12.3 % (2022: EUR 2.3 billion) and reaches the lower end of 2023 forecast
Green economy objects continue their strong growth
CM2 increases by 15.3 % to EUR 426.3 million (2022: EUR 369.6 mi [ … ]
Thu, 04.01.2024
Jungfraubahn Holding AG
4 January 2024
Ad hoc announcement pursuant to Art. 53 LR
Jungfrau Railway Group – More than 1 million guests visit the Jungfraujoch - Top of Europe
In an ad hoc announcement pursuant to Art. 53 of the Listing Rules, Jungfraubahn Holding AG announces that the visitor numbers in 2023 increased significantly again compared to the [ … ]
Wed, 03.01.2024
Evotec SE
DR WERNER LANTHALER TO STEP DOWN AS CEO
REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION
DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO
SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION
EVOTEC CONFIRMS GUIDANCE 2023
Hamburg, Germany [ … ]
Wed, 03.01.2024
Evotec SE
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo [ … ]